Status:
UNKNOWN
Spyglass+RFA Versus Cytobrush+RFA for Extrahepatic Cholangiocarcinoma
Lead Sponsor:
First People's Hospital of Hangzhou
Conditions:
Extrahepatic Cholangiocarcinoma
Malignant Biliary Obstruction
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
With the development of endoscopic technology, endoscopic retrograde cholangiopancreatography (ERCP) has been widely used in the diagnosis and treatment of extrahepatic cholangiocarcinoma.In patients ...
Detailed Description
Endoscopic retrograde cholangiopancreatography (ERCP) has been used as the primary method for the diagnosis of biliary strictures and the treatment of extrahepatic cholangiocarcinoma. However, the acc...
Eligibility Criteria
Inclusion
- Age \>18 years ;
- Patients with high suspicion of extrahepatic cholangiocarcinoma such as unexplained bile duct stenosis or elevated CA19-9 were found according to relevant imaging studies or symptoms;
- Willing to abide by the research procedures and sign the informed consent.
Exclusion
- Myocardial infarction within 3 months;
- Renal insufficiency (Scr\>177 umol/L);
- Serious cardiovascular and cerebrovascular or respiratory diseases before surgery;
- Preoperative shock manifestations, such as hypotension ( Systolic blood pressure \<90mmHg) or increased heart rate (\>120 beats/min);
- Pregnancy and lactation;
- Allergic to NSAIDs; Other clinical observation trials or those who have participated in other clinical trials within 60 days;
- Cases deemed inappropriate by the investigator (such as those with clear contraindications to ERCP).
Key Trial Info
Start Date :
January 1 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
October 31 2023
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT05233293
Start Date
January 1 2021
End Date
October 31 2023
Last Update
August 15 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hangzhou First People's Hospital
Hangzhou, Zhejiang, China, 31006